7.6 C
Alba Iulia
Saturday, January 23, 2021

Eli Lilly Drug Fails in COVID-19 hospitalization trials

Must Read

Bitcoin tumbles down 10 percent on fears of US crackdown

The price of bitcoin plunged more than 10 percent amid fears of a US regulatory crackdown on...

Wall Street rallies on inauguration day, Biden breaks Hoover’s record for stock gains

US stocks closed at record highs Wednesday as President Joe Biden was sworn in as the 46th president...

Rapper Jay-Z launches $10 million fund for minority-owned pot companies

Music mogul, Jay-Z has started an investment fund to help minority marijuana entrepreneurs break into the booming...

Eli Lilly said its investigational monoclonal antibody bamlanivimab — one of the agents used in treating former New Jersey Gov. Chris Christie, has failed to improve outcomes in hospitalized COVID-19 patients. The ACTIV-3 clinical trial is being run by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and is the only study evaluating the efficacy of bamlanivimab in hospitalized COVID-19 patients.

In a prepared statement, the company said that based on an updated dataset from the trial reviewed on October 26, no additional COVID-19 patients in this hospitalized setting will receive bamlanivimab. This recommendation was based on trial data suggesting that bamlanivimab is unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease. In this updated dataset, differences in safety outcomes between the groups were not significant.

Lily stated that all other studies of bamlanivimab remain ongoing, including ACTIV-2, the NIH-sponsored study in recently diagnosed mild to moderate COVID-19 patients; BLAZE-1, Lilly’s ongoing Phase 2 trial in people recently diagnosed with COVID-19 in the ambulatory (non-hospitalized) setting, studying bamlanivimab as monotherapy and in combination with etesevimab; and BLAZE-2, Lilly’s Phase 3 study of bamlanivimab for the prevention (prophylaxis) of COVID-19 in residents and staff at long-term care facilities. Based on data from BLAZE-1, Lilly submitted a request for EUA for bamlanivimab for the treatment of recently diagnosed mild to moderate COVID-19 illness in high-risk patients to the U.S. FDA in early October.

The statement concluded that while there was insufficient evidence that bamlanivimab improved clinical outcomes when added to other treatments in hospitalized patients with COVID-19, we remain confident based on data from Lilly’s BLAZE-1 study that bamlanivimab monotherapy may prevent progression of the disease for those earlier in the course of COVID-19.

- Advertisement -
- Advertisement -

Latest News

Bitcoin tumbles down 10 percent on fears of US crackdown

The price of bitcoin plunged more than 10 percent amid fears of a US regulatory crackdown on...

Wall Street rallies on inauguration day, Biden breaks Hoover’s record for stock gains

US stocks closed at record highs Wednesday as President Joe Biden was sworn in as the 46th president — with the new commander-in-chief...

Rapper Jay-Z launches $10 million fund for minority-owned pot companies

Music mogul, Jay-Z has started an investment fund to help minority marijuana entrepreneurs break into the booming cannabis business.

Chipotle And The Shawn Mendes Foundation team up to launch sustainability grants

Chipotle Mexican Grill has partnered with Shawn Mendes and the Shawn Mendes Foundation to launch "Wonder Grants" supporting young innovators in sustainability, as well...

Jobless Numbers: 965,000 new claims as COVID-19 pressures labor market

The federal jobless claims numbers are out and it shows 965,000 new applications were filed for unemployment benefits last week — an...
- Advertisement -

More Articles Like This

- Advertisement -